The Struggles of India’s Vaccine Giant

When the coronavirus hit, the Serum Institute of India, the world’s largest vaccine maker, seemed uniquely positioned to help. It struck a deal with AstraZeneca, promising a billion vaccine doses to low- and middle-income nations. 

Earlier this year, a ban instituted by Prime Minister Narendra Modi put a stop to those plans. 

What has that meant for the nations promised millions of doses?

Guest: Emily Schmall, a South Asia correspondent for The New York Times based in New Delhi. 

Sign up here to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter

Background reading: 

For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday. 

Previous Post
Next Post